MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says

MT Newswires Live07-30

MannKind's (MNKD) top-line data from the phase 1b INFLO-1 study evaluating nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis is "positive," Wedbush said in a Thursday note.

The firm said nintedanib data indicated a comparable cough rate and a significantly higher plasma Cmax, and therefore, more efficient delivery to the deep lung, compared to a nebulized formulation.

Guidance on the timing for data readout from the second phase of the trial is expected in H2 once there is clarity on the pace of patient enrollment, Wedbush said.

The firm said that "positive" INFLO-1 data marks an important forward step for MannKind as it builds a diversified product portfolio with proven technology to target a multi-billion-dollar market opportunity.

Wedbush has an outperform rating and an $8 price target on the stock.

Shares of the company were up 4% in Thursday trading.

Price: 4.01, Change: +0.16, Percent Change: +4.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655980174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655980174","market":"nz","top_or_hot":-1,"title":"MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> MannKind's (MNKD) top-line data from the phase 1b INFLO-1 study evaluating nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis is \"positive,\" Wedbush said in a Thursday note.</p><p>The firm said nintedanib data indicated a comparable cough rate and a significantly higher plasma Cmax, and therefore, more efficient delivery to the deep lung, compared to a nebulized formulation.</p><p>Guidance on the timing for data readout from the second phase of the trial is expected in H2 once there is clarity on the pace of patient enrollment, Wedbush said.</p><p>The firm said that \"positive\" INFLO-1 data marks an important forward step for MannKind as it builds a diversified product portfolio with proven technology to target a multi-billion-dollar market opportunity.</p><p>Wedbush has an outperform rating and an $8 price target on the stock.</p><p>Shares of the company were up 4% in Thursday trading.</p><p>Price: 4.01, Change: +0.16, Percent Change: +4.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-30 23:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> MannKind's (MNKD) top-line data from the phase 1b INFLO-1 study evaluating nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis is \"positive,\" Wedbush said in a Thursday note.</p><p>The firm said nintedanib data indicated a comparable cough rate and a significantly higher plasma Cmax, and therefore, more efficient delivery to the deep lung, compared to a nebulized formulation.</p><p>Guidance on the timing for data readout from the second phase of the trial is expected in H2 once there is clarity on the pace of patient enrollment, Wedbush said.</p><p>The firm said that \"positive\" INFLO-1 data marks an important forward step for MannKind as it builds a diversified product portfolio with proven technology to target a multi-billion-dollar market opportunity.</p><p>Wedbush has an outperform rating and an $8 price target on the stock.</p><p>Shares of the company were up 4% in Thursday trading.</p><p>Price: 4.01, Change: +0.16, Percent Change: +4.03</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655980174","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655980174","pubTimestamp":1785426114,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MannKind's (MNKD) top-line data from the phase 1b INFLO-1 study evaluating nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis is \"positive,\" Wedbush said in a Thursday not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MNKD":"曼恩凯德生物医疗","BK4584":"避孕概念"},"translate_title":"Wedbush 表示，1b 期 INFLO-1 研究的 MannKind 顶线数据“积极”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind's (MNKD) top-line data from the phase 1b INFLO-1 study evaluating nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis is \"positive,\" Wedbush said in a Thursday note.The firm said nintedanib data indicated a comparable cough rate and a significantly higher plasma Cmax, and therefore, more efficient delivery to the deep lung, compared to a nebulized formulation.Guidance on the timing for data readout from the second phase of the trial is expected in H2 once there is clarity on the pace of patient enrollment, Wedbush said.The firm said that \"positive\" INFLO-1 data marks an important forward step for MannKind as it builds a diversified product portfolio with proven technology to target a multi-billion-dollar market opportunity.Wedbush has an outperform rating and an $8 price target on the stock.Shares of the company were up 4% in Thursday trading.Price: 4.01, Change: +0.16, Percent Change: +4.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655980174","isCrawlerRequest":true}